• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

MycetOS: Harnessing the power of open source to develop treatments for a most neglected disease

Home > Stories

MycetOS: Harnessing the power of open source to develop treatments for a most neglected disease

Researcher handling samples in a laboratory
10 Nov 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Mycetoma has long been one of the most neglected tropical diseases, affecting the poorest populations in the most remote areas. The disease is a chronic slow-growing infection which comes in either bacterial (actinomycetoma) or fungal (eumycetoma) form. As existing treatments for the fungal form of mycetoma have only a 35% cure rate, amputation is often the only way to save patients.

Associate Professor Wendy van de Sande, from the Medical Microbiology and Infectious Diseases Department at Erasmus University Medical Center (Erasmus MC) based in Rotterdam, Netherlands, has over 20 years of experience in mycetoma research. We spoke to her about the challenging journey of seeking treatment for the disease through the Mycetoma Open Source project (MycetOS), an innovative and unique way of carrying out drug discovery research.

Tell us about MycetOS. When and why was it launched?

MycetOS began towards the end of 2017 with the aim of building a global network of scientists to drive lead optimization of new compounds targeting madurella mycetomatis, the main causative agent of fungal mycetoma. Unfortunately, drug screening for mycetoma is not being done on a large scale. Companies have not put the much-needed effort into finding new drugs for NTDs in general.

The Erasmus MC lab was at the time the only lab screening for antifungal agents, and there was a need to do more to find treatments for mycetoma patients. MycetOS came from the need to research and get more knowledge about treatment molecules and how to get the most effective drug to treat the disease. The molecules are sourced from partner organizations or manufactured by chemists.

MycetOS uses an open source approach to discover new treatments for mycetoma. Open source refers to a transparent working practice where anyone can participate in the project in real time by sharing data and ideas. This means there is a form of shared ownership which ensures that underlying methods and data are public domain.

MycetOS progresses drug discovery efforts through community-driven, in-kind scientific contributions and a robust, fully transparent online presence. All ideas and results are published immediately in real time to an open-access database, free of intellectual property constraints. Using this radically open approach, MycetOS aims to identify potential new treatments in a transparent and inclusive way.

Why is MycetOS important?

Pharmaceutical companies rarely develop novel drugs for skin NTDs, especially mycetoma. There is an urgent need to step into this void. There is currently only one treatment for eumycetoma, theantifungal drug itraconazole that is administered for at least 6 months after which the lesion is surgically removed. To prevent recurrence, at least another 6 months of antifungal treatment is given.

However, the drug is expensive and has considerable side effects. Sadly, a large proportion of patients will get a recurrent infection and eventually amputation is often performed. This situation has caused mycetoma patients to lose jobs, become socially stigmatized and often stop schooling or lose the ability to find a life partner. The bacterial variant of mycetoma can be treated with antibiotics only and does not require surgery.

The objective of MycetOS is to find a new drug for eumycetoma, preferably a drug that will work without the need for surgery and in a relatively shorter time. Although this plan might seem ambitious, it is not impossible.

Who are the partners involved in MycetOS and what is the role of Erasmus MC?

MycetOS is open to anyone willing to participate, including academia, industry, even high school students. Since the beginning, the University of Sydney, University College London, DNDi, Medicines for Malaria Venture (MMV), and Erasmus MC have been core partners. The universities in Sydney and London as well as DNDi design and make new molecules based on the hits we had in the biological evaluation done at Erasmus MC.

This evaluation determines if candidate compounds can inhibit the growth of madurella mycetomatis, and which compounds are the most potent at doing so. The most potent ones are then tested in vivo, in larval models: we infect larvae with the fungus and see which drug compounds are the best at inhibiting the growth of the fungus and therefore at reducing the burden of infection.

Since its inception, what are some of the milestones of the MycetOS project?

We started with 400 compounds and have so far screened 1,200 compounds from three MMV libraries in addition to the fenarimols (compounds from DNDi/Epichem library initially developed for treating Chagas disease) to identify lead compounds. One of the lead compounds was a fenarimol analogue that could inhibit fungal growth.

Furthermore, based on the hits we obtained, additional fenarimols were synthesized by students from the University of Sydney and University College London. We found out that certain chemical properties seemed to be important to be able to penetrate the fungus in vivo. To date, almost 200 fenarimol analogues have been screened.

When we started with the MycetOS project, we solely focused on madurella mycetomatis, which is the main causative agent of mycetoma. Since then, we have included some other causative agents such as falciformispora senegalensis because we found out that there are differences between the causative agents in terms of susceptibility towards different drugs.

This is an important finding and could indicate that before prescribing treatment, proper diagnosis needs to be done to determine which causative agent is causing the disease. In future, it will be important to develop medication that is active against all fungi that cause mycetoma.

Almina Yusuf Hassan Balel - mycetoma patient
Doctors and healthcare workers examine a patient at the Mycetoma Research Center in Sudan

What could be the impact of MycetOS on the diagnosis and treatment of mycetoma?

Discovering that different causative agents respond differently to antifungal drugs is crucial, because it means that diagnosing the causative agent correctly is very important when starting mycetoma treatment.

However, the most important outcome of MycetOS is the identification of novel drugs. So far, we have identified very interesting compounds that are already either in use or in clinical trials for other conditions. Among those identified hits are fosravuconazole, the drug currently clinically investigated for mycetoma in Sudan; olorofim, a drug currently in clinical study for other fungal diseases; and fenbendazole, which is used for helminth infections in animals.

Another significant impact of MycetOS on the treatment of mycetoma could be the design of combination therapies, since we have for the first time identified compounds with different modes of action. This was not possible before since all compounds demonstrated to be active previously were acting on the same biochemical pathway.

What could be the impact of MycetOS on mycetoma patients?

MycetOS will allow us to identify more compounds able to treat mycetoma patients. This means that clinicians should in the future have more options to be able to treat the condition. Hopefully this will result in tailor-made treatment for each patient that in turn will hopefully result in shorter treatment durations, eliminate surgeries, and most importantly prevent recurrences.

Are there some notable challenges in the MycetOS project?

Lack of funding is the biggest challenge. All the universities participating are paying from their own resources, which threatens the sustainability of the project.  

Furthermore, the fungus madurella mycetomatis is not an easy fungus to work with. It has a slow growth rate that takes up to a week and does not form spores like other fungi. That makes designing an infection model even more challenging. However, with good planning we have managed to get tremendous results in a short time.

When do you think the MycetOS project could lead to available treatment options for mycetoma patients?

This depends on the outcomes of the project. Some of the compounds identified are already approved for other conditions or in clinical trials. They could rapidly progress towards a clinical trial for mycetoma patients, as their safety profiles are already known. However, compounds that are made from scratch in laboratories will take much longer to reach patients.

‘It is wrong that after all this time, we still don’t have a solution for this infection. A solution is possible. All we need to do is find it to end the suffering.’

Wendy van de Sande

Photo credit: Abraham Ali-DNDi; Wendy van de Sande

Drug discovery Partnership Mycetoma

Read, watch, share

Loading...
Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
25 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

Healthcare workers looking into microscopes
Press releases
30 Nov 2022

Acoziborole: Investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo